The entrepreneur who has founded and sold off a number of science companies has said his focus is now to bring to market better non-narcotic drugs which will help to cure the USA’s opioid epidemic. 17 November 2016
German family-owned drugmaker Grünenthal has announced its recent acquisition of a USA-based clinical-stage, specialty pharmaceutical company. 17 November 2016
uniQure says it has completed a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value. 15 November 2016
Russian drugmaker Biocad has announced that it has successfully completed registration of a generic of glatiramer acetate, a drug for the treatment of multiple sclerosis, reports The Pharma Letter’s local correspondent. 14 November 2016
Investors in the beaten down biotech sector finally got an unexpected reprieve this week, thanks mainly due to the unexpected "clean sweep" of the US Congress and the presidency by the Republican party. 13 November 2016
The schizophrenia market across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%. 10 November 2016
Positive top-line results were announced last month by Ireland-headquartered Alkermes (Nasdaq: ALKS) for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), says analyst. 9 November 2016
An Australian biotech which specializes in the discovery and development of protein-based therapeutics has announced a second deal in as many days – this time by licensing its Alzheimer's disease-specific shark antibodies to a Dutch firm. 8 November 2016
Lexicon Pharmaceuticals has acquired exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed with pharma major Bristol-Myers Squibb. 7 November 2016
US drugmaker Abbott (NYSE: ABT) has officially commissioned a new line for the production of gelatine capsules at its Veropharm plant in the Russian city of Belgorod. 4 November 2016
Lundbeck saw its shares leap 7.8% to 231.90 Danish kroner this morning, after it raised its full-year revenue and profit forecasts after reporting stronger than expected third-quarter earnings. 2 November 2016
UK-based Mundipharma International has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the opioid overdose reversal treatment Nyxoid (intranasal naloxone spray). 2 November 2016
Businesses in Australia can now apply for a licen
se to cultivate cannabis for medicinal purposes, to manufacture medicinal cannabis products or to conduct medicinal cannabis related research under the Medicinal Cannabis Scheme. 31 October 2016
Biogen posted a record set of results late yesterday, showing that third-quarter 2016 revenues rose 6% to $296 billion, beating analysts’ forecasts of $2.91 billion. 27 October 2016
Closely-held US biotech firm Alzheon has announced the publication of data that shows for the first time a ‘gene-dose’ effect for a drug targeting Alzheimer’s disease to treat a subpopulation of up to 65% of Alzheimer’s patients with a genetic risk factor. 25 October 2016
The US market for major depressive disorders (MDD) will rise from $2.4 billion in 2015 to $4.6 billion by 2025, at a strong compound annual growth rate (CAGR) of 6.6%, a new study finds. 25 October 2016
A new report published by the UK government today, puts forward a number of recommendations aimed at speeding up the process by which the NHS implements newly developed drugs and medical procedures. 24 October 2016
Alkermes’ shares jumped 47% to $64 in after hours trading from a Nasdaq close at $43.51 on Thursday, after the company announced positive top-line results from FORWARD-5, the third Phase III efficacy study to read out from the FORWARD pivotal program for ALKS 5461. 21 October 2016
The US Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). 21 October 2016
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024